The introduction of several new therapeutic agents, predominantly biologic therapies, has
transformed the management of moderate and severe psoriasis in recent years. A novel oral …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …

Introduction The broad and sustained efficacy of apremilast for psoriasis has been
demonstrated in randomized and real-world observational studies. Data from Central and …

Materials and Methods: This was retrospective, single-center, longitudinal, observational
cohort study where the total study period was 24 weeks. Effectiveness parameters were the …

Objectives To investigate the survival of apremilast in a cohort of psoriasis patients treated
with apremilast in a Greek hospital. Methods A retrospective cross-sectional study examined …

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis.
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …

Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …